[1] S. Hidayat, F. Maulana Ibrahim, C. Suhandi, and M. Muchtaridi, “A systematic review: Molecular docking simulation of small molecules as anticancer non-small cell lung carcinoma drug candidates,” © 2022 J. Adv. Pharm. Technol. Res. | Publ. by Wolters Kluwer-Medknow, 2022, doi: 10.4103/japtr.japtr_311_21.
[2] Y. Tian et al., “Identification and expression analysis of 26 oncogenes of the receptor tyrosine kinase family in channel catfish after bacterial infection and hypoxic stress,” Comp. Biochem. Physiol. Part D. Genomics Proteomics, vol. 14, pp. 16–25, 2015, doi: 10.1016/J.CBD.2015.02.001.
[3] S. Talukdar, L. Emdad, S. K. Das, and P. B. Fisher, “EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells,” Adv. Cancer Res., vol. 147, pp. 161–188, Jan. 2020, doi: 10.1016/BS.ACR.2020.04.003.
[4] E. Levantini, G. Maroni, M. Del Re, and D. G. Tenen, “EGFR signaling pathway as therapeutic target in human cancers,” Seminars in Cancer Biology. Academic Press, 2022. doi: 10.1016/j.semcancer.2022.04.002.
[5] Helga Wecker and Cornelius F. Waller, “Afatinib.pdf.” 2016.
[6] M. D. Ward and D. J. Leahy, “Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry,” J. Biol. Chem., vol. 290, no. 3, pp. 1570–1579, Jan. 2015, doi: 10.1074/JBC.M114.612085.
[7] K. Shi et al., “Emerging strategies to overcome resistance to third-generation EGFR inhibitors,” J. Hematol. Oncol. 2022 151, vol. 15, no. 1, pp. 1–44, Jul. 2022, doi: 10.1186/S13045-022-01311-6.
[8] V. Assadollahi, B. Rashidieh, M. Alasvand, A. Abdolahi, and J. A. Lopez, “Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S,” J. Cell. Biochem., vol. 120, no. 8, pp. 13046–13055, Aug. 2019, doi: 10.1002/jcb.28575.
[9] M. A. Mansour, A. M. AboulMagd, S. H. Abbas, H. M. Abdel-Rahman, and M. Abdel-Aziz, “Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review,” RSC Adv., vol. 13, no. 27, pp. 18825–18853, 2023, doi: 10.1039/d3ra02347h.
[10] H. Wecker and C. F. Waller, “Afatinib,” Recent Results Cancer Res., vol. 211, pp. 199–215, 2018, doi: 10.1007/978-3-319-91442-8_14.
[11] T. E. Stinchcombe, “The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer,” Curr. Treat. Options Oncol., vol. 17, no. 4, Apr. 2016, doi: 10.1007/S11864-016-0394-4.
[12] W. Y. Hung et al., “Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities,” Cell. Physiol. Biochem., vol. 51, no. 1, pp. 337–355, Nov. 2018, doi: 10.1159/000495233.
[13] B. Dai et al., “Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy,” PLoS One, vol. 10, no. 6, Jun. 2015, doi: 10.1371/JOURNAL.PONE.0123967.
[14] B. Kim, Y. S. Park, and Y. H. Kim, “Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer,” no. May 2020, pp. 372–385, 2021, doi: 10.1002/cam4.3635.
[15] J. Eberhardt, D. Santos-Martins, A. F. Tillack, and S. Forli, “AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings,” J. Chem. Inf. Model., vol. 61, no. 8, pp. 3891–3898, Aug. 2021, doi: 10.1021/ACS.JCIM.1C00203/SUPPL_FILE/CI1C00203_SI_002.ZIP.
[16] D. S. Wishart et al., “DrugBank: a knowledgebase for drugs, drug actions and drug targets,” Nucleic Acids Res., vol. 36, pp. 901–906, 2008, doi: 10.1093/nar/gkm958.
[17] “Chemistry Software, HyperChem, Molecular Modeling.” http://www.hypercubeusa.com/ (accessed Jan. 24, 2024).
[18] O. Trott and A. J. Olson, “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading,” J. Comput. Chem., vol. 31, no. 2, p. 455, Jan. 2010, doi: 10.1002/JCC.21334.
[19] “The PyMOL Molecular Graphics System, Version 4.6 Schrödinger, LLC.” https://pymol.org/2/ (accessed Jan. 27, 2024).
[20] “RCSB PDB: Homepage.” https://www.rcsb.org/ (accessed Jan. 25, 2024).
[21] S. A. Hollingsworth and R. O. Dror, “Molecular Dynamics Simulation for All,” Neuron, vol. 99, no. 6, pp. 1129–1143, Sep. 2018, doi: 10.1016/J.NEURON.2018.08.011.
[22] “GROMACS 2024.2 Manual”, doi: 10.5281/ZENODO.11148638.
[23] M. S. Valdés-Tresanco, M. E. Valdés-Tresanco, P. A. Valiente, and E. Moreno, “Gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS,” J. Chem. Theory Comput., vol. 17, no. 10, pp. 6281–6291, Oct. 2021, doi: 10.1021/ACS.JCTC.1C00645/SUPPL_FILE/CT1C00645_SI_001.PDF.
[24] B. R. Miller, T. D. McGee, J. M. Swails, N. Homeyer, H. Gohlke, and A. E. Roitberg, “MMPBSA.py: An Efficient Program for End-State Free Energy Calculations,” J. Chem. Theory Comput., vol. 8, no. 9, pp. 3314–3321, Sep. 2012, doi: 10.1021/CT300418H.
